EUVIMEDEUVIMED entdecken
Open Access

Drug‐induced liver injury ( DILI ) ascribed to non‐steroidal anti‐inflammatory drugs ( NSAIDs ) in the USA —Update with genetic correlations

Herbert L Bonkovsky iD, Marwan Ghabril iD, Paola Nicoletti, Andrew Dellinger, Robert J Fontana iD, Huiman Barnhart, Jiezhun Gu, Ann K Daly, Guruprasad P Aithal, Elizabeth J Phillips, David E Kleiner iD, US DILIN Investigators

Liver International · 2024

DOI: 10.1111/liv.15892 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Liver International, 2024. Verfasst von Herbert L Bonkovsky und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Wake Forest University School of Medicine and Atrium Health Wake Forest Baptist, Winston-Salem, North Carolina, USA. Hauptthemen laut MEDLINE: Anti-Inflammatory Agents, Non-Steroidal, Chemical and Drug Induced Liver Injury, Diclofenac. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCRR NIH HHS, NIDDK, NIDDK NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To describe patients with NSAID‐DILI, including genetic factors associated with idiosyncratic DILI.

Methods

In DILIN, subjects with presumed DILI are enrolled and followed for at least 6 months. Causality is adjudicated by a Delphic approach. HLA sequencing of multiethnic NSAID‐DILI patients and HLA allele imputation of matching population controls were performed following overall, class and drug‐based association analysis. Significant results were tested in a non‐Hispanic White (NHW) case–control replication cohort.

Results

Between September 2004 and March 2022, causality was adjudicated in 2498, and 55 (41 [75%] women) were assessed as likely due to NSAIDs. Median age at onset was 55 y (range 22–83 y). Diclofenac was the causative drug in 29, celecoxib in 7, ibuprofen in 5, etodolac and meloxicam each in 4. Except for meloxicam and oxaprozin ( n = 2), the liver injury was hepatocellular with median R 15–25. HLA‐DRB1*04:03 and HLA‐B*35:03 were significantly more frequent in NSAID‐DILI patients than in non‐NSAID DILI controls. Interestingly, 85% of the HLA‐DRB1*04:03 carriers developed DILI due to the use of acetic acid derivative NSAIDs, supporting the hypothesis that HLA‐DRB1*04:03 could be a drug and/or class risk factor. HLA‐B*35:03 but not HLA‐DRB1*04:03 association was confirmed in the independent NHW replication cohort, which was largely driven by diclofenac.

Conclusions

Despite prevalent use, NSAID‐DILI is infrequent in the United States. Diclofenac is the most commonly implicated, and adherence to warnings of risk and close observation are recommended. The increased frequency of HLA‐B*35:03 and DRB1*04:03 , driven by diclofenac, suggests the importance of immune‐mediated responses.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Inflammatory Agents, Non-SteroidalChemical and Drug Induced Liver InjuryDiclofenacHumansFemaleMiddle AgedAdultAgedMaleUnited StatesAged, 80 and overCase-Control StudiesYoung AdultRisk FactorsCelecoxib

Stichwörter der Autor:innen

HLA (human leucocyte antigen)diclofenacgeneticsibuprofenidiosyncratic drug‐induced liver injuryimmune‐mediated liver disease

Substanzen

Anti-Inflammatory Agents, Non-SteroidalDiclofenacCelecoxib

Autor:innen und Institutionen

  • Department of Internal Medicine, Wake Forest University School of Medicine and Atrium Health Wake Forest Baptist, Winston-Salem, North Carolina, USA.
  • Department of Internal Medicine, Indiana University School of Medicine and IU Hospital, Indianapolis, Indiana, USA.
  • Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
  • Duke Molecular Physiology Institute, Durham, North Carolina, USA.
  • Department of Internal Medicine, University of Michigan School of Medicine, Ann Arbor, Michigan, USA.
  • Department of Biostatistics and Bioinformatics, Duke Clinical Research Institute, Durham, North Carolina, USA.

ORCID-Profile: Herbert L Bonkovsky, Marwan Ghabril, Robert J Fontana, David E Kleiner

Förderung

  • NCRR NIH HHS
  • NIDDK
  • NIDDK NIH HHS
  • NCATS NIH HHS
  • NHGRI NIH HHS
  • National Institute of Diabetes and Digestive and Kidney Diseases

Zitieren

APA

Bonkovsky, H. L., Ghabril, M., Nicoletti, P., Dellinger, A., Fontana, R. J., Barnhart, H., Gu, J., Daly, A. K., Aithal, G. P., Phillips, E. J., Kleiner, D. E., & US DILIN Investigators (2024). Drug‐induced liver injury ( DILI ) ascribed to non‐steroidal anti‐inflammatory drugs ( NSAIDs ) in the USA —Update with genetic correlations. Liver International. https://doi.org/10.1111/liv.15892

Vancouver

Bonkovsky HL, Ghabril M, Nicoletti P, Dellinger A, Fontana RJ, Barnhart H, et al. Drug‐induced liver injury ( DILI ) ascribed to non‐steroidal anti‐inflammatory drugs ( NSAIDs ) in the USA —Update with genetic correlations. Liver International. 2024. doi:10.1111/liv.15892

BibTeX
@article{Bonkovsky2024,
  author = {Bonkovsky, Herbert L and Ghabril, Marwan and Nicoletti, Paola and Dellinger, Andrew and Fontana, Robert J and Barnhart, Huiman and Gu, Jiezhun and Daly, Ann K and Aithal, Guruprasad P and Phillips, Elizabeth J and Kleiner, David E and US DILIN Investigators, US DILIN Investigators},
  title = {Drug‐induced liver injury ( DILI ) ascribed to non‐steroidal anti‐inflammatory drugs ( NSAIDs ) in the USA —Update with genetic correlations},
  journal = {Liver International},
  year = {2024},
  doi = {10.1111/liv.15892}
}
Kostenlos starten →